Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Tesla Raises Cybertruck Prices by $5,000 in US 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Add as a preferred source on Google
CHESTERBROOK, Pa., May 02, 2018 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at the Deutsche Bank 43rd Annual Healthcare Conference on Tuesday, May 8th, 2018, at 3:30 p.m. EDT in Boston, MA.
To join a live audio webcast of the presentation, please visit the Investor section of the Company’s website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on providing better, safer therapies to patients in pain. The Company has leveraged breakthrough science to discover and develop its investigational product, oliceridine injection, for the management of moderate-to-severe acute pain. Oliceridine has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration, and is intended to provide healthcare providers an innovative new option for patients who require an intravenous opioid. The Company also has an early stage pipeline of new chemical entities targeting novel mechanisms of action, including TRV250 for acute migraine, neuropathic pain, and other indications.
Contacts
Trevena, Inc.
Investors:
Jonathan Violin, Ph.D.
Senior Vice President, Scientific Affairs & Investor Relations Officer
610-354-8840 x231
[email protected]
or
Media:
Public Relations
[email protected]
